Clinical investigation of change of bone-related marker between denosumab and zoledronic acid in patients with treatment-naive,bone-metastasis prostate cancer:prospective, multiinstitutional,cohort study
Not Applicable
Recruiting
- Conditions
- treatment-naive prostate cancer with bone metastasis
- Registration Number
- JPRN-UMIN000018268
- Lead Sponsor
- Department of Renal and Urologic Surgery, Asahikawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
history of radiation therapy to bone metastasis, history of dental treatment within 6 weeks of entry,Grade 4 renal insuffuciency such as eGFR under 30 or serum creatinine over 3
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change of bone marker
- Secondary Outcome Measures
Name Time Method adverse events, skeletal related event-free survival, PSA progression-free survival,change of renal function